Cell Therapy Human Raw Materials Market Report 2026

The cell therapy human raw materials market size has grown rapidly in recent years. It will grow from $3.36 billion in 2025 to $4.03 billion in 2026 at a compound annual growth rate (CAGR) of 19.8%. The growth in the historic period can be attributed to early adoption of stem cell therapies, expansion of academic cell therapy research, growth in clinical trials for cell-based treatments, increasing availability of human-derived biological materials, rising investment in regenerative medicine research.

The cell therapy human raw materials market size is expected to see rapid growth in the next few years. It will grow to $7.71 billion in 2030 at a compound annual growth rate (CAGR) of 17.6%. The growth in the forecast period can be attributed to surge in approved cell therapy products, rising demand for allogeneic and autologous therapies, increasing regulatory scrutiny on raw material quality, expansion of commercial-scale cell therapy manufacturing, growth of oncology-focused cell therapies. Major trends in the forecast period include rising demand for xeno-free and human-derived raw materials, increasing emphasis on gmp-grade and clinical-grade inputs, growing standardization of human cell sourcing and processing, expansion of raw material requirements for advanced cell therapies, long-term supply agreements for critical human raw materials.

The growing use of regenerative medicine is poised to propel the cell therapy human raw materials market forward. Regenerative medicine encompasses therapeutic strategies that repair, replace, or regenerate impaired tissues and organs through stem cells, gene therapy, tissue engineering, or other biological processes to restore typical function. Its adoption is surging thanks to progress in biotechnology, deeper insights into cellular processes, rising interest in personalized treatments, and solutions for unmet clinical needs. The cell therapy human raw materials market bolsters regenerative medicine by providing key biological materials needed to create consistent, potent, and dependable cell-based therapies. For example, in August 2023, the Alliance for Regenerative Medicine - a US-based nonprofit - reported 2,760 developers of cell, gene, and tissue-engineering therapies worldwide in Q1 2023, a 101% increase from 1,369 in Q1 2022. Thus, the expanding adoption of regenerative medicine is fueling the cell therapy human raw materials market.

Major companies in the cell therapy human raw materials market are placing greater emphasis on creating chemically defined cell culture media to speed up cell therapy development. A cell culture medium serves as a nutrient-rich solution that supplies vital nutrients, growth factors, and controlled environmental conditions required for cells to grow and multiply in vitro, away from their natural setting. For example, in May 2023, Lonza Group AG - a Switzerland-based healthcare manufacturing firm - introduced TheraPEAK T-VIVO Cell Culture Medium. This product offers a chemically defined, serum-free, and animal component-free formula, along with recombinant proteins, better support for cell culture and expansion, and application guidance, all of which promote consistency, safety, and adherence to regulations in cell therapy production. This medium marks key technological progress through its removal of animal-derived components, chemically defined makeup, and regulatory-compliant features, ultimately boosting safety, quality, and compliance.

In July 2025, Sartorius AG, a Germany-based life science group, acquired MatTek Corp for an undisclosed sum. Through this deal, Sartorius seeks to broaden its cell technology offerings by incorporating MatTek’s sophisticated human cell-based microtissue models into its Lab Products & Services division, thus enhancing its drug development platform. MatTek Corporation, a US-based biotechnology firm, focuses on creating 3D microtissue models and primary cells that better replicate human tissue structure, providing more reliable, economical, and ethical options compared to conventional 2D cultures.

Major companies operating in the cell therapy human raw materials market are Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group Ltd., Sartorius AG, Miltenyi Biotec, Bio-Techne Corporation, STEMCELL Technologies, PromoCell GmbH, AllCells LLC, BioIVT LLC, ACROBiosystems, Sartorius CellGenix GmbH, RoosterBio Inc., Takara Bio Inc., Grifols S.A., Charles River Laboratories, WuXi AppTec, Catalent Inc., Fujifilm Cellular Dynamics Inc., Orgenesis Inc.

North America was the largest region in the cell therapy human raw materials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell therapy human raw materials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cell therapy human raw materials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the cell therapy human raw materials market by increasing the cost of imported human serum, specialized supplements, reagents, and cryoprotectants essential for cell therapy manufacturing. these impacts have been most significant across cell culture media and supplement segments, particularly in north america and europe where reliance on globally sourced human-derived materials is high. asia-pacific manufacturers have faced procurement delays due to cross-border compliance and customs requirements. however, tariffs have encouraged local sourcing of human raw materials and strengthened domestic donor networks, supporting supply chain resilience and regulatory alignment.

The cell therapy human raw materials market research report is one of a series of new reports that provides cell therapy human raw materials market statistics, including cell therapy human raw materials industry global market size, regional shares, competitors with a cell therapy human raw materials market share, detailed cell therapy human raw materials market segments, market trends and opportunities, and any further data you may need to thrive in the cell therapy human raw materials industry. This cell therapy human raw materials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cell therapy human raw materials consist of biological substances sourced from humans, including cells, tissues, and blood components. These serve as essential building blocks in developing and producing cell-based therapeutic products. They play roles across multiple phases of cell therapy manufacturing to develop treatments for conditions like cancer, genetic disorders, and degenerative diseases.

The primary product categories for human raw materials in cell therapy include cell culture media, cell culture serum, cell culture supplements, reagents and buffers, and others. Cell culture media consist of solutions that supply nutrients and create an environment for cell growth outside their natural habitat, which is vital for laboratory-based cell research. These products support diverse cell therapies, such as dendritic cell therapy, natural killer (NK) cell therapy, stem cell therapy, and T-cell therapy, serving end users like biopharmaceutical and pharmaceutical companies, contract research organizations (CROs), and contract manufacturing organizations (CMOs), along with academic and research institutions.

The cell therapy human raw materials market consists of sales of primary cells, stem cell banks, tissue scaffolds, cryopreservation media, cell separation products, and extracellular matrices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.